Viracta Therapeutics, Inc.
VIRX
$0.0175
-$0.0038-17.84%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.74% | -37.43% | -32.32% | -28.79% | -23.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.07% | -8.85% | 0.00% | 0.21% | -3.23% |
| Operating Income | 3.07% | 8.85% | 0.00% | -0.21% | 3.23% |
| Income Before Tax | 9.09% | 14.07% | 5.64% | -3.78% | 5.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.09% | 14.07% | 5.64% | -3.78% | 5.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.09% | 14.07% | 5.64% | -3.78% | 5.36% |
| EBIT | 3.07% | 8.85% | 0.00% | -0.21% | 3.23% |
| EBITDA | 3.12% | 9.12% | 0.39% | 0.35% | 3.67% |
| EPS Basic | 10.75% | 15.84% | 7.63% | -1.49% | 7.64% |
| Normalized Basic EPS | 10.74% | 15.82% | 7.62% | -1.49% | 7.65% |
| EPS Diluted | 11.04% | 16.09% | 7.91% | -1.56% | 7.33% |
| Normalized Diluted EPS | 10.74% | 15.82% | 7.62% | -1.49% | 7.65% |
| Average Basic Shares Outstanding | 2.00% | 2.07% | 2.16% | 2.21% | 2.49% |
| Average Diluted Shares Outstanding | 2.00% | 2.07% | 2.16% | 2.21% | 2.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
